April 14, 2025
The U.S. Food and Drug Administration (FDA) and Novo Nordisk are warning people not to use counterfeit semaglutide 1.0 mg (Ozempic injection) found in the US […]
April 14, 2025
The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of […]
April 11, 2025
The National Institute for Health and Care Excellence (NICE) has recommended a new twice-daily tablet for some patients in England with locally advanced or metastatic breast […]
April 10, 2025
The Dexcom G7 continuous glucose monitor (CGM) will now last 15 days, up from the previous 10-day version. The US Food and Drug Administration’s clearance of […]
April 10, 2025
The National Institute for Health and Care Excellence (NICE) has recommended erdafitinib (Balversa, Johnson & Johnson) as a treatment option for adults with unresectable or metastatic […]
April 9, 2025
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and […]
April 4, 2025
The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is […]
April 1, 2025
The US Food and Drug Administration (FDA) has approved a perioperative durvalumab (Imfinzi, AstraZeneca) regimen for adults with muscle-invasive bladder cancer. Specifically, the indication is for […]
March 31, 2025
The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen […]